Format

Send to

Choose Destination
Br J Cancer. 2019 Feb;120(4):398-403. doi: 10.1038/s41416-019-0376-y. Epub 2019 Feb 6.

Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.

Author information

1
Women's College Research Institute, Toronto, ON, Canada.
2
Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada.
3
Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, NE, Canada.
4
Program in Cancer Genetics, McGill University, Montreal, QC, Canada.
5
Beth Israel Deaconess Medical Center, Boston, MA, USA.
6
Department of Medicine, University of Chicago, Chicago, IL, USA.
7
Toronto Sunnybrook Regional Cancer Center, Toronto, ON, Canada.
8
Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
9
Women's College Research Institute, Toronto, ON, Canada. steven.narod@wchospital.ca.

Abstract

BACKGROUND:

To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer.

METHODS:

Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation. Data were abstracted from the medical record and pathology report. We analysed the effects of ER status and other variables on breast cancer specific survival using a Cox proportional hazards model.

RESULTS:

Three hundred ninety women with breast cancer and a BRCA2 mutation were included in the analysis. The mean follow-up time was 12.3 years (range 1-39 years) and 89 subjects died (22.8%). In the multivariate analysis, women with ER-positive tumours were more likely to die than women with ER-negative tumours (HR 2.08, 95% CI 0.99-4.36, pā€‰=ā€‰0.05), and this was of borderline significance. For the 233 women with ER-positive tumours the 20-year survival rate was 62.2%, compared to 83.7% for 58 women with ER-negative tumours (pā€‰=ā€‰0.03).

CONCLUSIONS:

The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer.

PMID:
30723304
DOI:
10.1038/s41416-019-0376-y

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center